High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib

Background: Regorafenib improves progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are available. Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previously associated with outcome in chemotherapy trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Amatu, Alessio, Schirripa, Marta, Tosi, Federica, Lonardi, Sara, Bencardino, Katia, Bonazzina, Erica, Palmeri, Laura, Patanè, Damiano Alfio, Pizzutilo, Elio Gregory, Mussolin, Benedetta, Bergamo, Francesca, Alberti, Giulia, Intini, Rossana, Procaccio, Letizia, Arese, Marco, Marsoni, Silvia, Nichelatti, Michele, Zagonel, Vittorina, Siena, Salvatore, Bardelli, Alberto, Loupakis, Fotios, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Barault, Ludovic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640154/
https://www.ncbi.nlm.nih.gov/pubmed/31355139
http://dx.doi.org/10.3389/fonc.2019.00622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640154/
https://www.ncbi.nlm.nih.gov/pubmed/31355139
http://dx.doi.org/10.3389/fonc.2019.00622

Ejemplares similares